Figure 3. Thromboembolism, Bleeding, Cancer Progression, and All-Cause Mortality Within 180 Days in the Intention-to-Treat Randomized Population and Low-Risk Population According to Subgroup.

The intention-to-treat population included all eligible participants classified as being at high risk of thromboembolism who underwent randomization and eligible participants classified as low risk. Markers indicate hazard ratios, and horizontal lines indicate 95% CIs. CRNM indicates clinically relevant nonmajor; GI, gastrointestinal; PY, person-years.

^aP = .10 for interaction (GI vs lung cancer).

^bP = .65 for interaction (GI vs lung cancer).

^cP = .52 for interaction (GI vs lung cancer).

^dP = .63 for interaction (GI vs lung cancer).

^eP = .29 for interaction (GI vs lung cancer).

^fP = .93 for interaction (GI vs lung cancer).